Semaglo 0.5 mg/0.375 ml (SC Injection)

0.5 mg pre-filled syringe: ৳ 560.00

Medicine Details

Category Details
Generic Semaglutide
Company Ziska pharmaceuticals ltd
Also available as
Semaglo 3 mg tablet Semaglo 7 mg tablet Semaglo 025 mg injection Semaglo ob 025 mg injection Semaglo ob 05 mg injection Semaglo ob 1 mg injection Semaglo ob 17 mg injection Semaglo ob 24 mg injection

Indications

  • Adjunct to diet and exercise for type 2 diabetes mellitus
  • Reduction of major adverse cardiovascular events for type 2 diabetes mellitus
  • Chronic weight management for obesity
  • Initial body mass index (BMI) for obesity management

Pharmacology

  • GLP-1 analogue with 94% sequence similar to human GLP-1
  • Stimulates insulin secretion and lowers glucagon secretion
  • Reduces blood glucose in a glucose dependent manner
  • Delays gastric emptying
  • Reduces appetite, body weight, and body fat mass

Dosage & Administration

  • Semaglutide tablet administration instructions
  • Starter dose for diabetes
  • Maintenance dose for diabetes
  • Additional glycemic control for diabetes
  • Semaglutide injection starting dose for diabetes
  • Semaglutide injection dose escalation for diabetes
  • Dose adjustment for obesity
  • Switching between Semaglutide injection and tablet
  • Injection site and administration precautions

Interaction

  • Potential impact on absorption of concomitantly administered oral medicinal products
  • Caution with oral medicinal products requiring rapid gastrointestinal absorption

Contraindications

  • Hypersensitivity to active substance or excipients

Side Effects

  • Hypoglycemia with insulin or sulfonylurea
  • Gastrointestinal disorders
  • Nausea
  • Diarrhea
  • Vomiting
  • Abdominal pain
  • Constipation
  • Allergic reactions
  • Injection site reactions
  • Lipodystrophy
  • Pruritus
  • Rash

Pregnancy & Lactation

  • Avoid use during pregnancy
  • Discontinue before planned pregnancy
  • Avoid use during breastfeeding

Precautions & Warnings

  • Avoid use in type 1 diabetes mellitus and diabetic ketoacidosis
  • Discontinue if pancreatitis is suspected
  • Monitoring for diabetic retinopathy

Use in Special Populations

  • Efficacy and safety in children and adolescents
  • No dose adjustment needed based on age
  • No dose adjustment for mild, moderate, or severe renal impairment
  • Not recommended for end-stage renal disease
  • No dose adjustment for hepatic impairment
  • Exercise caution in treating patients with hepatic impairment

Overdose Effects

  • Reported overdose cases
  • Most commonly reported adverse reaction
  • No specific antidote for overdose
  • Supportive treatment for overdose
  • Dose adjustment when added to existing therapy
  • Guidelines for missed dose

Therapeutic Class

  • GLP-1 receptor agonists

Storage Conditions

  • Temperature storage range
  • Avoid freezing
  • Keep out of reach of children

Related Brands